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Background: The association between subclinical hypothyroidism (sHT) and cognitive impairment
or risk of dementia is not well-defined, especially in the elderly, where the assessment of central
nervous system function is challenging. The aim of this systematic review andmeta-analysis was to
evaluate the possible effect of sHT on cognitive decline and the risk of dementia.
Methods: Cognitive function was the primary outcome, evaluated as composite endpoint of in-
cidenceorprevalenceofdementiaordifferenceofMiniMental State Examination,WechslerAdult
Intelligence Scale, and Wechsler Memory Scale-Revised scores.
Results: Thirteen studies were included in the meta-analysis. A significant risk of cognitive alter-
ation was observed only in sHT individuals younger than age 75 years: composite endpoint odds
ratio (OR) 1.56 (95% confidence interval [CI] 1.07–2.27, P  .02, I2  82.5%), risk of dementia OR
1.81 (95% CI 1.43–2.28, P .01, I2 35%). Mean serum thyroid-stimulating hormone (TSH) levels
and the OR of composite endpoint were positively correlated. No significant effect of sHT was
foundwhen considering all the studies as awhole: composite endpointOR 1.26 (95%CI 0.96–1.66,
P .09, I2 87.2%), risk of dementia OR 1.42 (95%CI, 0.97–2.07, P .07, I2 66.8%),MiniMental
State Examination mean difference 0.059 (95% CI 0.464 to 0.346 P  .78, I2  51.8%).
Conclusions: This meta-analysis demonstrates a relationship between sHT and cognitive impair-
ment only in individuals younger than 75 years of age and those with higher TSH concentrations.
No correlation was found while considering all the studies as a whole. The lack of utilization of
age-related serum TSH reference ranges and consequent potential misdiagnosis of sHT in older
people may account for this. (J Clin Endocrinol Metab 100: 4240–4248, 2015)
Subclinical thyroid dysfunction is common a conditionin the general population, especially in older people.
In fact, mild thyroid failure or subclinical hypothyroidism
(sHT), defined as serum thyroid-stimulating hormone
(TSH) concentrationabove theupper limit of the reference
range in the face of normal free T4 (FT4) and free T3 levels,
represents one of the most frequently observed diseases in
the elderly (1–3). Several pathological entities,mainly rep-
resentedby chronic autoimmune thyroiditis, are known to
be associated with sHT pathogenesis (1). It has been es-
timated that sHT affects 5–10% of adult population with
an increasedprevalence inwomenandolder people (4–6).
However, it has been shown that serum TSH rises in nor-
mal healthy elderly individuals and, by excluding people
whose serum TSH is below the 97.5th percentile for age
(around 7 mIU/L in octogenarians) the actual prevalence
of sHT is likely lower (6–8). Most subjects with sHT do
not show specific symptoms, whereas others experience
symptoms that resemble those observed in overt hypothy-
roidism, although to a lesser extent (1, 8). Considering the
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subtle clinical presentation of sHT, the evaluation of the
impact of mild thyroid failure on cognition could be a
challenge, especially in specific populations such as older
people or patientswith chronic diseases. The effect of sHT
on cognitive function has been investigated in several pre-
clinical studies, and a growing body of evidence has sug-
gested a relevant link between thyroid hormones and cen-
tral nervous system (CNS) (9). However, the actual
associationbetween sHTandcognitive impairmentor risk
of dementia has not been completely elucidated, especially
in the elderly, in whom the assessment of CNS function is
more challenging (9, 10). In this setting, conflicting data
have been reported in large, population-based studies,
leading to uncertain conclusions regarding the association
between mild thyroid failure and memory/cognition im-
pairment (11–17). Moreover, no meta-analyses on this
topic have been published. For these reasons, we carried
out a systematic review and meta-analysis to evaluate the
effect of sHT on cognition and on the risk of dementia.
Materials and Methods
The study was designed according to the Preferred Reporting
Items for Systematic Reviews andMeta-Analyses statement (18)
and recommendations from the Cochrane Collaboration and
Meta-analysis of Observational Studies in Epidemiology (19)
using a methodology extensively described in a previous publi-
cation of our group written following previous studies (20, 21).
Search strategy
The MEDLINE, Web of Science, Cochrane CENTRAL, and
Scopus databases were searched for articles in all languages pub-
lished until November 2014. Gray literature (ie, everything that
is not peer-reviewed and controlled by commercial publishers)
was not considered as a priority asset of our systematic review,
and only formally published English articles were selected. Stud-
ies were identified and evaluated by three of the authors (G.Pas,
G.Pag., F.M.) using the major medical subject heading “hypo-
thyroidism” and “dementia” combined with the following text
and key words (the following is an example for MEDLINE):
(subclinical AND (“hypothyroidism” [MeSH Terms] OR (“hy-
pothyroidism” [MeSH Terms] OR “hypothyroidism”))) AND
Figure 1. Meta-analysis flow chart.
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(((((((((“dementia” [MeSH Terms] OR “alzheimer disease”
[MeSH Terms]) OR (“dementia” [MeSH Terms] OR “demen-
tia”OR“dementias”))OR(“dementia” [MeSHTerms]OR“de-
mentia” OR “amentia”)) OR (“dementia” [MeSH Terms] OR
“dementia” OR “amentia”)) OR (“dementia” [MeSH Terms]
OR “dementia” OR (“senile” AND “paranoid” AND “demen-
tia”))) OR (“dementia” [MeSH Terms] OR “dementia” OR
(“senile” AND “paranoid” AND “dementias”))) OR (“demen-
tia” [MeSH Terms] OR “dementia” OR (“familial” AND “de-
mentia”) OR “familial dementia”)) OR (“dementia” [MeSH
Terms] OR “dementia” OR (“familial” AND “dementia”) OR
“familial dementia”)) OR ((((“Mild Cognitive Impairment”
[Mesh] OR (cognitive AND impairment)) OR (cognitive AND
impairments))OR (“mild cognitive impairment” [MeSHTerms]
OR (“mild” AND “cognitive” AND “impairment”) OR “mild
cognitive impairment” OR (“mild” AND “cognitive” AND
“impairments”) OR “mild cognitive impairments”)) OR cogni-
tive)). Additional eligible studies were identified screening the
reference lists of studies included in our analysis.
Study selection
All selected titles and abstracts were independently reviewed
by twoauthors (G.Pas.,G.Pag.). Studieswere excluded if the title
and/or abstract were not appropriate for the aim of the review.
Full textswere subsequently obtained for eligible studies orwhen
the relevance of an article could not definitively be excluded.
Disagreement was resolved by consensus and by opinion of a
third reviewer (F.M.), when necessary. Selected studies were el-
igible if they met the following criteria: published data, cross-
sectional, case control, or longitudinal analysis enrolling at least
15 patients with subclinical hypothyroidism, well-defined nor-
mal upper limit of TSH value, and defined and unique commer-
cial product to runTSHassay. Reviews, case reports, nonhuman
studies, and abstracts or conference proceedings were excluded.
Risk of bias in included studies
The quality of the included studies was assessed by New-
castle-Ottawa Scale (NOS) (22). NOS is characterized by eight
items including selection, comparability, and exposure (case-
control studies), or outcome (cohort studies). The scale ranged
from zero to nine stars, with the highest degree representing the
greatest methodological quality. Disagreement was resolved by
consensus and by opinion of a third reviewer (F.M.). The pres-
ence of publication bias was explored by performing the test for
asymmetry of the funnel plot by Egger, which consists of the
linear regression of normalized estimate effect (divided by its
standard error) against precision (reciprocal of the standard er-
ror of the estimate) (23, 24).
Table 1. Study Characteristic and Quality Score (Newcastle-Ottawa Scale)
Study Type sHT Definition TSH Assay
Baldini et al (1997) (33) Case control TSH exceeding the upper normal limits by 20%
(4.6 mU/liter) or more (in at least two
consecutive occasions) associated with
normal FT4 and FT3
IRMA Allegro HS-TSH, Nichols
Institute Diagnostics, San
Juan Capistrano, CA
Formiga et al (2014) (40) Cohort study TSH 5 mU/liter, FT4 10–26 pmol/liter MABs Roche Diagnostics
Jorde et al (2006) (15) Cohort study TSH 5–10 mU/liter, FT4 9–22 pmol/liter in at
least two consecutive occasions
Hoffman-La Roche
Park et al (2010) (17) Cohort study TSH 4.1 mU/liter, FT4 0.7–1.8 ng/liter TSH: CIS Bio International,
Gif-sur-Yvette
Parsaik et al (2014) (32) Cross-sectional TSH 5–10 mU/liter, FT4 1.01–1.79 ng/dl TSH Mayo Clinic Protocol
Roberts et al (2006) (14) Cohort study TSH 5.5 mU/liter, FT4 9–20 pmol/liter Adiva Centaur Bayer Diagnostic
Wijsma et al (2013) (34) Cohort study TSH 4.5 mU/liter, FT4 12–18 pmol/liter in at
least two consecutive occasions
Roche Elecsys 2010
Yamamoto et al (2011) (35) Cohort study NA NA
Silva et al (2013) (36) Cross-sectional TSH 4–19.9 U/liter, FT4 0.8–1.19 ng/dl Immunolite 2000
Tan et al (2008) (12) Cohort study TSH 1.8–2.1 mU/literb London Diagnostics, Eden
Prairie, Minnesota
Forti et al (2012) (37) Cross-sectional TSH 4.50 mU/liter, FT4 10.3–25.7 pmol/liter Roche Elecsys 2010
Resta et al (2012) (39) Cross-sectional TSH 3.6 mU/liter, FT4 8–17 pmol/liter Vedere ILSA Study Ref 24
Kalmijn et al (2000) (38) Cohort study TSH 4 mU/liter, FT4 11–25 pmol/liter TSH Lumitest (Hennin,
Berlin, Germany)
a The 97.5th percentile of TSH adjusted for age was obtained by the general National Health and Nutrition Examination Survey cohort values as by
Boucai et al (8).
b The limits indicated the third percentile for men and women, respectively.
FT3, free T3; NA, not available.
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Data extraction
Two reviewers (G.Pas, G.Pag.) independently completed the
data extraction by using a standardized form.Disagreementwas
resolved by consensus and the opinion of a third reviewer (F.M.),
when required. Detailed information was recorded on study
year, author first name, type of study, sHT definition, commer-
cial product used to run the TSH assay, cognitive function eval-
uation (prevalence or incidence of dementia, Mini Mental State
Examination [MMSE], Wechsler Memory Scale-Revised, total
memory quotient, and Wechsler Adult Intelligence Scale scores,
sample size, and characteristics of patients (including possible
thyroid medication).
Outcomes
Primary outcome (cognitive function) was assessed as com-
posite endpoint, derived fromone of the following parameters as
available in each study: incidence or prevalence of dementia,
reducedMMSE,WechslerMemoryScale-Revised, totalmemory
quotient, and Wechsler Adult Intelligence Scale scores. Second-
ary outcome was the mean difference of MMSE score and the
prevalence of dementia.
Statistical analysis
The odds ratio (OR) was calculated for each outcome of the
composite endpoint exceptMMSE, inwhich themeandifference
of scores was assessed. The results were pooled using the inverse
variance method. When standard deviation (SD) was not avail-
able, missing SDwas imputed and changes in endpointmeasures
from baseline to follow-up were obtained according to the Co-
chrane Handbook (25).
For binary outcomes, OR and 95% confidence intervals (CI)
were calculated for each outcome by using the intention-to-treat
principle. The choice to use OR was driven by the retrospective
design of the meta-analysis based on published studies that var-
ied in design, subjects’ population, primary outcome measure,
and research quality (26). Heterogeneity was assessed using I2
statistic that accounts of between-study (or interstudy) variabil-
ity as opposed to within-study (or intrastudy) variability. Be-
cause of latent clinical heterogeneity, random effect model was
used to synthesize data instead of a fixed-effect model, inde-
pendently from statistical evidence of heterogeneity (27). Het-
erogeneity was considered substantial if I2 value was greater
than 25% (28).
All reported test resultswere two-tailed andPvalue .05was
considered significant. Data analysis was performed with
STATA (Statacorp, version 12.0).
Sensitivity analysis
To investigate the influence of individual studies on the sum-
mary risk estimate, we undertook one-study-removed analysis
Table 1. Continued
Thyroid
Medication
Allowed
(Yes, No)
TSH Upper
Limit >97.5th
Percentile
Adjusted
for Agea
Main
Cognitive
Endpoint
Number
sHT
Number
Controls
sHT
Female
(%)
Controls
Female
(%)
sHT
Mean Age
(Years)
Controls
Mean Age
(Years)
Newcastle-
Ottawa
Scale
No Yes Total memory
quotient
19 17 100 100 52.2 50.3 5
No No Dementia 20 282 55 60.3 85 85 7
No Yes Composite
cognitive
function
28 102 30 78.68 61.7 61.3 7
No No Dementia 164 754 55.5 56.6 76.8 76.5 6
No No Wechsler
Memory
Scale-Revised
141 1450 49.6 43.9 81.7 80.0 6
No No MMSE 168 5554 64 50 74 73 6
No No MMSE 161 4.928 64 48.6 75.6 75.3 6
No NA MMSE 15 214 53,3 65,9 80,1 80,9 5
No No MMSE 43 235 81.4 76.6 81.2 80.3 6
Yes, maximum
6% of the
whole cohort
No Dementia 559 1133 59.4 57.9 72 71 6
Yes No Dementia 217 423 93 113 74 71.9 6
No No Dementia 42 283 64.3 44.2 74.3 74.3 6
Yes, maximum
0.4% of the
whole cohort
No Dementia 170 1552 NA 6
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by omitting one study in each turn and recalculating the pooled
estimates on remaining studies using the metaninf command (29).
To explore the influence of potential effect modifiers on composite
endpoint, a meta-regression analysis was performed with the
metareg command to test age, sex (male
%), and baseline TSH (STATA) (30).
For all meta-regression analyses, a
random effect model was used to take
intoaccount themeanof adistributionof
effects across studies. In fact, the random
effect model more appropriately provides
wider confidence intervals for the regres-
sion coefficients than a fixed effect analy-
sis, if residual heterogeneity exists (31).
The weight used for each study was
the inverse of the sum of the within trial
variance and the residual between trial
variance to correspond to a random effect
analysis. To estimate the additive (between-
study) component of variance -2, the re-
stricted maximum likelihood method was
used to take into account the occurrence of
residual heterogeneity, not explained by the
potential effect modifiers (31).
Results
A total of 135 articleswere identified
by the initial search up to November
4, 2014, 27 of which were retrieved
for more detailed evaluation and 13
were finally included in the meta-
analysis (Figure 1). In detail, we
found four cross-sectional, one case-
control, and seven cohort studies,
with an age range from 50.3 to 81.2
years (12, 14, 15, 17, 32–40) (Table
1).Heterogeneity among studieswas
observed for the method of TSH
measurement and for the upper limit
of normal TSH level, with values
ranging from 2.1 to 5.5 mIU/L. The
mean values of serum TSH ranged
from 5.5 to 12.0 mIU/L in the sub-
clinical hypothyroid groups and
from 1.2 to 2.3 mIU/L in the control
groups (Table 1). The composite
endpoint was obtained from all the
studies, theMMSEscore in eight (14,
17, 34–37, 39, 40), and the risk of
dementia in six studies (12, 17, 37–
40) (Figure 2). The quality of in-
cluded studies was moderate or
good, varying from five to seven
NOS stars (Table 1).
Primary and secondary outcomes
Overall, no significant difference was found for the
composite endpoint: OR1.26 (95%CI 0.96–1.66,P .09,
Figure 2. Pooled analyses (log of OR) for: (A) primary composite endpoint (incidence or
prevalence of dementia, MMSE score, miscellaneous cognitive function scales, Wechsler Memory
Scale-Revised score, and total memory quotient); (B) MMSE score (standardized mean difference);
(C) incidence or prevalence of dementia (log of OR). Reported data are stratified by age (older
and younger than 75 years).
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I2  87.2%). The mean difference for MMSE score was
0.059 (95% CI0.464 to 0.346, P .78, I2 51.8%)
and the OR for dementia 1.42 (95% CI 0.97–2.07, P 
.07, I2 66.8%). However, the analysis of the composite
endpoint and the risk of dementia showed significant re-
sults when age was taken into account. A significant as-
sociation between sHT and cognitive alterations or de-
mentia was obtained in studies with mean age of the
enrolled population younger than 75 years, whereas no
effectwasobserved in the six studies enrollingolderpeople
(Figure 2). In detail, in the former studies, the OR of the
composite endpoint and risk of dementia was 1.56 (95%
CI 1.07–2.27, P  .02, I2  82.5%) and 1.81 (95% CI
1.43–2.28,P .01, I2 35%), respectively. Accordingly,
the meta-regression analysis of OR of the composite end-
point and mean age confirmed a significant association
between age and the composite endpoint (Figure 3). It is
worth noting that the risk of composite endpoint was pos-
itively related with the degree of TSH elevation (ß 0.28,
P .005; data available for five studies),whereas no effect
was obtained by stratifying for gender. Finally, the sec-
ondary analysis performed using the mean difference of
MMSE scores as endpoint failed to show any association
between sHTand cognitive function, regardless of age and
gender stratification.
Sensitivity analysis and publication bias
One-study-removed analysis showed a significant ef-
fect of sHT on the composite endpoint (OR 1.324, 95%
C.I. 1.004–1.746, P  .047) only when the study by
Yamamoto et al was removed (2011). However, by using
the mean difference ofMMSE scores and risk of dementia
as endpoints, a significant effect was never obtained. Pub-
lication bias was detected by Egger’s linear regression
method for both primary composite
outcome and risk of dementia (P 
.02 and P  .01, respectively),
whereas the analysis on MMSE
scores did not show any publication
bias (P  .38) (Figure 4).
Discussion
Overall, this systematic review and
meta-analysis indicates that mild
thyroid failure is not associated with
cognitive alterations, defined by the
diagnosis of dementia or the decline
of cognitive functionatMMSE.Dur-
ing the past 3 decades, a large num-
ber of studies investigated the rela-
tionship between sHT and cognitive
decline; however, these studies presented a huge hetero-
geneity in the enrolled population, especially for age, gen-
der, and clinical setting. These differences need to be taken
into account when analyzing the clinical endpoints of the
single study and, as suggested by our analysis on compos-
ite endpoint and riskof dementia,mild thyroid failuremay
lead to cognitive alterations and increased risk of dementia
inindividualsyoungerthanage75years (9, 41).This finding
should be interpreted with caution considering that it was
not confirmed by analyzing the age stratified mean differ-
ence of MMSE scores. However, it is worth mentioning
that the low sensitivity of MMSE, especially for detecting
low/mild cognition impairment and the ceiling effect of
this scale (42, 43), made theMMSE score inconclusive for
very slight deficit of cognitive function (12, 33, 39, 44, 45).
Several basic and clinical studies have suggested a strong
relationship between thyroid hormones and CNS devel-
opment and function (9). However, conflicting data exist
on the relationship between sHT and cognitive impair-
ment (46). Naturalistic studies have provided evidences of
the negative effect of full-blown hypothyroidism on cog-
nitive function, especially during the childbearing period
and in infants (47, 48). Moreover, some studies docu-
mented a specific alteration of thememory domain in sHT
patients (12, 33, 39, 44), whereas others reported possible
or no effect onother cognitive domains (14, 15, 17, 44, 45,
49, 50). Based on the heterogeneity of these results, we
created a composite outcome, comprehensive of different
endpoints (dementia, cognitive function, and intelligence
scales) to obtain a sufficient statistical power and to guar-
antee reliability of the results. By using this composite
endpoint, an association between sHT and the risk of de-
mentia was found in patients younger than age 75 years
Figure 3. Meta-regression analysis between age and log of OR.
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but not in older people. A possible explanation of this
discrepancy could be the overdiagnosis of sHT in the el-
derly resulting from a lack of utilization of age-related
serum TSH reference ranges in all the studies included in
the meta-analysis (51). Indeed, the physiological shift of
the serum TSH distribution curve toward upper values
during normal agingmay lead tomisclassification of older
subjects as having sHT (6, 8). According to the National
Health and Nutrition Examination Survey study, the
97.5th percentile for normal serum TSH is 3.9 mIU/L in
individuals younger than 49 years and 6.3 in those older
than 80 (8). In other words, it is likely that by the same
serum TSH value young individuals had “true” mild thy-
roid failure, whereas older ones (80 years) did not. This
could have led to an underestimation of the risk of cog-
nitive alteration associated with sHT in the elderly. An-
other interesting result of the present meta-analysis is rep-
resented by the significant positive relationship between
the OR for the composite endpoint and serum TSH value
in sHT groups, although this result has been observed in
a secondary evaluation of five studies. This finding would
suggest that cognitive decline is increasingly related to the
extent of thyroid failure, in line with the recommendation
of the international guidelines for the diagnosis of demen-
tia (10, 52). Finally, we did not confirm a gender suscep-
tibility to sHT, as reported by Tan et al in a longitudinal
study (12).
The inclusion of individuals taking thyroid hormone
replacement therapy was allowed only in three studies
(enrolling subjects younger than age 75 years) (Table 1).
An association of sHT with cognitive alterations and in-
creased risk of dementia was nonetheless shown in two of
the three studies. Thus, the inclusion
of patients taking LT4 therapy seems
not to interfere with the main result
of the meta-analysis.
In this setting, it could be interest-
ing to evaluate the potential effect of
LT4 replacement therapy on cogni-
tion. But scanty data exist on this
topic, generally obtained in young
individuals, without randomized
study design (45).
Taken together, we can conclude
from our results that a possible in-
teraction between mild thyroid defi-
ciency and CNS function could be
present in subjects younger than age
75 years, whereas no effect was doc-
umented in the oldest old (75
years). In this setting, it is worth not-
ing that a similar figure has been de-
scribed also for cardiovascular and
stroke risk of sHT patients (53–55).
Strengths and limitations of this meta-analysis
Some limitations arepresent in thismeta-analysis. First,
we focused only on English-language literature. The in-
cluded studies were not restricted to specific range of age
and sex and were designed as naturalistic analysis (cross-
sectional, case control, and cohort studies) with different
data collection (prospective and retrospective).We should
also mention as a possible bias the heterogeneity of in-
cluded studies in terms of sHT definition (based on the
upper limit of TSH) and in cognitive evaluation (diagnosis
of dementia and cognitive scales). Moreover, none of the
meta-analyzed studies used age adjusted expected ranges,
leading to the possible misclassification of older subjects
as having sHT. Moreover, the diagnosis of sHT was gen-
erally based on a single measurement of TSH, without at
least a second confirmatory assessment, with potential
misclassification of euthyroid subjects only suffering from
transient elevation of serum TSH. Finally, the meta-anal-
ysis presented significant regression bias regarding the pri-
mary composite endpoint and risk of dementia. Despite
these limitations, the present meta-analysis has increased
the statistical power by pooling results of the single stud-
ies. Therefore, the total number of the cases and controls
was sufficiently large to support the study conclusionof an
age-related increased risk for dementia in sHT subjects.
Conclusions
This systematic review and meta-analysis demonstrates a
relationship between sHT and cognitive function only doc-
Figure 4. Funnel plot of standard errors by logOR.
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umented in individualsyounger than75yearsand thosewith
higherTSHconcentrations.No correlationwas foundwhile
considering all the studies as awhole. The lack of utilization
of age-related serum TSH reference ranges and consequent
potential overdiagnosis of sHT in older peoplemay account
for this. Future studies using multiple age-related TSH ref-
erence ranges will provide a better understanding of the risk
of cognitive deficits in sHT patients.
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